**The *Pseudomonas aeruginosa* lectin LecB causes integrin
internalization to facilitate crawling of bacteria underneath host cells**

3

4 Running title: **Integrin internalization by the lectin LecB**

5

6 Roland Thuenauer^{a,b,c,d,#}, Alessia Landi^{a,b}, Anne Trefzer^{a,b}, Silke Altmann^{a,b}, Sarah
7 Wehrum^{a,b}, Thorsten Eierhoff^{a,b}, Britta Diedrich^e, Jörn Dengjel^e, Alexander Nyström^f,
8 Anne Imberty^g, Winfried Römer^{a,b,#}

9

10 ^a Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany

11 ^b BIOS Centre for Biological Signalling Studies, Albert- Ludwigs-University
12 Freiburg, Freiburg, Germany

13 ^c Advanced Light and Fluorescence Microscopy Facility, Centre for Structural
14 Systems Biology (CSSB), Hamburg, Germany

15 ^d Department of Biology, University of Hamburg, Hamburg, Germany

16 ^e Department of Biology, University of Fribourg, Fribourg, Switzerland; and
17 Department of Dermatology, Medical Center - Albert-Ludwigs-University Freiburg,
18 Freiburg, Germany

19 ^f Department of Dermatology, Medical Center - Albert-Ludwigs-University Freiburg,
20 Freiburg, Germany

21 ^g Univ. Grenoble Alpes, CNRS, CERMAV, Grenoble, France

22

23 [#] Correspondence to Winfried Römer (winfried.roemer@bioss.uni-freiburg.de,
24 Schänzlestraße 18, Albert- Ludwigs-University Freiburg, 79104 Freiburg, Germany)

25 or Roland Thuenauer (roland.thuenauer@cssb-hamburg.de, Notkestraße 85, CSSB c/o

26 DESY, 22607 Hamburg, Germany).

27

28 **Abstract**

29 The opportunistic bacterium *Pseudomonas aeruginosa* produces the fucose-specific
30 lectin LecB, which has been identified as virulence factor. LecB has a tetrameric
31 structure with four opposing binding sites and has been shown to act as crosslinker.
32 Here, we demonstrate that LecB strongly binds to the glycosylated moieties of β 1-
33 integrins on the basolateral plasma membrane of epithelial cells and caused rapid
34 integrin endocytosis. Whereas internalized integrins were degraded via a lysosomal
35 pathway, washout of LecB restored integrin cell surface localization, thus indicating a
36 specific and direct action of LecB on integrins to bring about their endocytosis.
37 Interestingly, LecB was able to trigger uptake of active and inactive β 1-integrins and
38 also of complete α 3 β 1-integrin - laminin complexes. We provide a mechanistic
39 explanation for this unique endocytic process by showing that LecB has the additional
40 ability to recognize fucose-bearing glycosphingolipids and caused the formation of
41 membrane invaginations on giant unilamellar vesicles. In cells, LecB recruited
42 integrins to these invaginations by crosslinking integrins and glycosphingolipids. In
43 epithelial wound healing assays, LecB specifically cleared integrins from the surface
44 of cells located at the wound edge and blocked cell migration and wound healing in a
45 dose-dependent manner. Moreover, the wild type *P. aeruginosa* strain PAO1 was able
46 to loosen cell-substrate adhesion in order to crawl underneath exposed cells, whereas
47 knockout of LecB significantly reduced crawling events. Based on these results we
48 suggest that LecB has a role in disseminating bacteria along the cell - basement
49 membrane interface.

50 **Importance**

51 *Pseudomonas aeruginosa* is a ubiquitous environmental bacterium that is one of the
 52 leading causes for nosocomial infections. *P. aeruginosa* is able to switch between
 53 planktonic, intracellular, and biofilm-based lifestyles, which allows it to evade the
 54 immune system as well as antibiotic treatment. Hence, alternatives to antibiotic
 55 treatment are urgently required to combat *P. aeruginosa* infections. Lectins, like the
 56 fucose-specific LecB, are promising targets, because removal of LecB resulted in
 57 decreased virulence in mouse models. Currently, several research groups are
 58 developing LecB inhibitors. However, the role of LecB in host-pathogen interaction is
 59 not well understood. The significance of our research is in identifying cellular
 60 mechanisms how LecB facilitates *P. aeruginosa* infection: We introduce LecB as new
 61 member to the list of bacterial molecules that bind integrins and show that *P.*
 62 *aeruginosa* can efficiently move forward underneath attached epithelial cells by
 63 loosening cell - basement membrane attachment in a LecB-dependent manner.

64 **1 Introduction**

65 *Pseudomonas aeruginosa* is a ubiquitous Gram-negative environmental bacterium. For
 66 humans it acts as an opportunistic pathogen and can cause severe infections,
 67 predominantly in cystic fibrosis patients (1) and immunocompromised individuals,
 68 such as HIV patients (2), patients receiving cancer treatment (3), patients with assisted
 69 ventilation (4), and patients with burn wounds (5). *P. aeruginosa* infections are
 70 difficult-to-treat because the bacterium has a high natural resistance to antibiotics and
 71 rapidly acquires new antibiotic resistances (6). In fact, several outbreaks caused by
 72 multidrug-resistant *P. aeruginosa* strains were recently reported (7, 8). In addition, the
 73 bacterium is able to adopt various lifestyles that allow it to evade the immune system
 74 as well as antibiotic treatment. In particular, *P. aeruginosa* can form biofilms (9) and
 75 invades and proliferates in host cells (10). These properties make *P. aeruginosa* an
 76 imminent threat for global health and therefore the World Health Organization (WHO)
 77 categorized *P. aeruginosa* with ‘Priority 1’ on its recently released ‘WHO priority
 78 pathogens list for research and development of new antibiotics’ (11), which highlights
 79 the need to develop novel treatment strategies for *P. aeruginosa* infections (12).

80

81 When infecting the human body, *P. aeruginosa* typically encounters polarized
 82 epithelial cell layers, which function as protective barriers (10). As an opportunistic
 83 bacterium, *P. aeruginosa* adapts its strategy according to the circumstances it
 84 encounters. It harnesses weak spots, for example sites where cells divide or are
 85 extruded, to proceed to the basolateral side of epithelia (13). *P. aeruginosa* has also
 86 been shown to have a propensity to enter and colonize wounded epithelia (10), and
 87 there is ample experimental evidence that loss of epithelial polarity increases
 88 detrimental effects of *P. aeruginosa* on host cells (10). In addition, *P. aeruginosa* has

evolved strategies to manipulate the polarity of host epithelial cells to facilitate infection (10, 14). When reaching the basolateral side, *P. aeruginosa* gets access to integrins, which are typically restricted to the basolateral plasma membrane of epithelial cells. Although integrins are well known as receptors for multiple pathogens (15–17), and previous studies have shown that *P. aeruginosa* is able to bind to $\alpha 5 \beta 1$ -integrins in nasal epithelial cells (18) and to $\alpha \nu \beta 5$ -integrins in lung epithelial cells (19), the specific roles for integrins for *P. aeruginosa* infection remain unclear.

P. aeruginosa produces two carbohydrate-binding proteins, so-called lectins, LecA and LecB, which are also named PA-IL and PA-IIL, respectively (20). Whereas LecA is galactophilic, LecB prefers fucose (20). LecB is transported to the outer bacterial membrane, where it binds to the porin OprF, resulting in its presentation at the outer surface of *P. aeruginosa* (21, 22). Several lines of evidence indicate that LecB is an important virulence factor. LecB-deficient *P. aeruginosa* are less pathogenic (23) and show diminished biofilm formation (21). In addition, LecB was found to abrogate ciliary beating in human airways (24) and to diminish tissue repair processes in lung epithelia (25). These findings raised the prospect to establish alternative treatment strategies for *P. aeruginosa* infections by blocking LecB, and stimulated ongoing efforts of several research groups to develop LecB inhibitors (26–31).

However, the functions of LecB remain difficult to pin down, because as a lectin it can bind to many different host cell receptors. Here, we demonstrate that integrins are major receptors of LecB. Moreover, we observed that LecB binding to integrins resulted in their rapid cellular uptake together with their basement membrane ligands. We provide a mechanistic explanation for this distinctive endocytosis process by

114 showing that LecB binding to fucose-bearing lipids induces membrane invaginations
 115 and, furthermore, LecB positions integrins in these invaginations by crosslinking
 116 integrins and lipids. As functional consequence, purified LecB caused inhibition of cell
 117 migration and abrogation of epithelial wound healing by specifically internalizing
 118 exposed integrins in cells at the wound edge. Furthermore, we could demonstrate that
 119 the wild type (wt) *P. aeruginosa* strain PAO1 is able to locally disturb cell adhesion
 120 and to crawl underneath epithelial cells. Importantly, knocking out LecB diminished
 121 the number of *P. aeruginosa* found underneath epithelial cells, thus implicating LecB
 122 as virulence factor enabling bacteria to colonize host tissue along the interface between
 123 cells and the basement membrane.

2 Results

2.1 Differential effects of LecB at the apical and basolateral side of polarized epithelial cells

When *P. aeruginosa* infects a human body, it typically encounters first the apical pole of epithelial cells. Through induced or pre-existing damages, the bacterium can access the basolateral cell pole of epithelial cells. Since the apical and basolateral plasma membrane of individual epithelial cells harbors distinct sets of membrane proteins and lipids, we investigated if LecB causes different effects when applied to the apical or basolateral side. We chose Madin-Darby canine kidney (MDCK) cells as model system because they reliably form polarized monolayers *in vitro* (32, 33) and have been already successfully used in *P. aeruginosa* infection studies (14, 34). Purified LecB was able to bind apical and basolateral plasma membranes of MDCK cells (Fig. S1A). Interestingly, apical application of LecB resulted in completely different responses of the host cells than basolateral application (Fig. 1A). After 6 h and 12 h of apical treatment with 50 µg/ml (4.3 µM) LecB the overall morphology of the cells was intact as evidenced by staining of β-catenin (red) that remained basolateral and GPI-GFP (green) that remained apical. In addition, tight junction integrity was not disturbed as demonstrated by the unchanged staining of ZO-1 (white in Fig. 1A) and the preserved trans-epithelial electrical resistance (TEER; Fig. 1B). In contrast, 6 h and 12 h of basolateral treatment with 50 µg/ml LecB resulted in rounded cell morphologies and severely disturbed epithelial polarity. GPI-GFP became localized all around the cells and tight junctions almost disappeared (Fig. 1A), which was corroborated by a drastic reduction of the TEER (Fig. 1B). Importantly, these effects cannot be explained by potential LecB-mediated apoptosis or necrosis (Fig. S1B-C). Yet, the observed consequences seem to be specific for LecB, because another fucose-binding lectin, *Ulex*

europaeus agglutinin I (UEA-I (35)), which did also bind to apical and basolateral plasma membranes of MDCK cells (Fig. S1D), did not cause apparent changes in cell morphology (Fig. S1E), nor did it influence the TEER (Fig. S1F).

Taken together, basolateral application of LecB dissolves epithelial polarity in MDCK cells, whereas another fucose-binding lectin, UEA-I, does not cause such effects.

2.2 Basolaterally applied LecB binds β 1-integrin and causes its internalization

To uncover the mechanisms of LecB-induced loss of epithelial polarity, we monitored the localization of cell adhesion receptors upon basolateral LecB stimulation. This revealed a rapid and efficient internalization of β 1-integrins (Fig. 1C). Interestingly, this effect was reversible after washout of LecB after 6 h (Fig. 1D), and the timing of β 1-integrin internalization and return to the cell surface correlated well with decrease and increase of the TEER (Fig. 1E).

To elucidate LecB-triggered β 1-integrin internalization, we first investigated if LecB binds to β 1-integrin. To this end we used LecB-biotin to precipitate LecB-receptor complexes with streptavidin beads. Western blot analysis of the precipitates showed that LecB-biotin is able to bind to β 1-integrins only when applied to the basolateral side (Fig. 2A). The binding of LecB-biotin to β 1-integrin appeared to be strong, since LecB-biotin was able to extract approximately 75% of total β 1-integrin when applied to the basolateral side, as quantified from the band intensities of the Western blot. In addition, fluorescently labeled LecB co-localized with internalized β 1-integrins (Fig. 2B) and was able to bind immunoprecipitated β 1-integrin in a far-Western assay in dependence of the β 1-integrin glycosylation status (Fig. 2C), which provides complementary evidence for the capacity of LecB to bind to glycosylated β 1-integrin.

In summary, LecB recognizes β 1-integrin at the basolateral cell surface and causes its rapid internalization.

2.3 α 3-integrin and laminin are also internalized and degraded upon basolateral LecB application

From the far-Western assay in Fig. 2C it can be seen that LecB recognized not only glycosylated β 1-integrin, but also other receptors that were presumably co-precipitated during β 1-integrin immunoprecipitation (blue arrows). Hence, in a next step we identified basolateral interaction partners of LecB by LecB-biotin co-precipitation followed by mass spectrometry analysis and found 65 profoundly enriched proteins (Table S1). This analysis revealed that LecB is able to pull down virtually all integrins expressed by MDCK cells (36), and also many proteins known to interact with integrins, such as tetraspanins, basigin, EGFR, were detected. From this it appears that integrins are major cellular receptors of LecB. We focused our further analysis on α 3 β 1-integrin and were able to demonstrate that α 3-integrins are co-internalized with β 1-integrins upon basolateral LecB application (Fig. 3A). Surprisingly, also the major ligands of α 3 β 1-integrin expressed by MDCK cells, laminin-332 and/or -511 (37), were co-internalized (Fig. 3B). This suggests that LecB is able to cause endocytosis of intact α 3 β 1-integrin – laminin complexes. To measure the dynamics of α 3 β 1-integrin internalization we carried out surface biotinylation experiments (38). These experiments confirmed the rapid LecB-triggered internalization of α 3- and β 1-integrin subunits (Figs. 3C - 3E). In addition, the surface biotinylation experiments revealed that also the intracellular amount of α 3- and β 1-integrin subunits decreased upon LecB stimulation, suggesting a degradation of internalized integrins. Consistently, LecB-mediated reduction of integrins was also detected when whole cell lysates were

subjected to Western blot analysis (Fig. S2A). Loss of integrins by degradation is further supported by our finding that internalized integrins after basolateral LecB treatment showed a time-dependent increase in co-localization with the late endosome marker Rab9 (Figs. S2B-C) and the lysosome marker Lamp1 (Figs. S2D-E). In the surface biotinylation experiments we were not able to distinguish between active and inactive $\beta 1$ -integrins. Thus, we devised an alternative strategy in which we applied activation-specific $\beta 1$ -integrin antibodies to the basolateral surface of live cells. This approach revealed that LecB internalizes active and inactive $\beta 1$ -integrins at similar kinetics (Figs. 3F – 3H and Fig. S3F), which indicates that the activation status of $\beta 1$ -integrins does not play an important role in LecB-mediated integrin internalization. Taken together, LecB binds integrins, including $\alpha 3 \beta 1$ -integrin, and causes their internalization and degradation regardless of their activation status and bound basement membrane ligands.

2.4 Membrane invagination by LecB and LecB-mediated crosslinking of fucosylated lipids with $\beta 1$ -integrin can explain LecB-triggered integrin internalization

Endogenous lectins, like galectin-3, were previously shown to be able to mediate integrin internalization (39, 40). The proposed mechanism for galectin-3-mediated integrin internalization is that galectin-3 is able to cause plasma membrane invaginations by binding to glycolipids and also drags integrins into the invaginated membrane regions by functioning as a crosslinker between glycolipids and integrins. Since LecB is a tetramer with four opposing fucose binding sites (41), which represents an ideal geometry for a potential crosslinker, we investigated if a galectin-like mechanism could explain LecB-mediated $\beta 1$ -integrin internalization.

In a first step we examined if binding of LecB to fucosylated glycosphingolipids is sufficient to induce membrane invaginations in giant unilamellar vesicles (GUVs) (42). Indeed, GUVs containing glycosphingolipids that bear the fucosylated Lewis a antigen (Fig. 4A) or other fucosylated glycosphingolipids (Fig. S3) showed invaginations immediately after LecB application, whereas control GUVs with the non-fucosylated glycosphingolipid lactotetraosylceramide (Lc4cer) did not (Fig. 4A). To investigate the relevance of this effect, we carried out experiments with energy-depleted cells, because under these conditions cellular machineries cannot pinch off vesicles, which previously led to well-visible membrane invaginations when other lipid-binding lectins like Shiga toxin were applied (42, 43). Indeed, LecB was able to induce plasma membrane invaginations in energy-depleted MDCK cells (Fig. 4B). Importantly, β 1-integrin co-localized with fluorescently labeled LecB at invaginations (Fig. 4B, magnification), thus implicating that LecB can recruit integrins to invaginations. Furthermore, we observed that basolateral LecB application led to marked clustering of endogenous galectin-3 (Fig. S4), which could suggest that LecB outcompetes galectin-3-integrin interaction.

In summary, LecB is able to cause membrane invaginations upon binding to fucose-bearing glycosphingolipids. Since LecB is also able to bind integrins and thus to crosslink lipids in membrane invaginations with integrins, this provides a mechanistic explanation for LecB-mediated integrin internalization.

2.5 LecB inhibits cell migration and epithelial wound healing

As an opportunistic pathogen *P. aeruginosa* mainly relies on, and exploits, extrinsic circumstances – like a wound – to gain access to the basolateral side of epithelia. In addition, integrin blocking, e.g. through antibodies, has been previously shown to

inhibit cell migration in wound healing assays (44). These considerations motivated us to investigate the effect of LecB on epithelial wound healing. Indeed, presence of LecB strongly inhibited collective cell migration and wound healing in MDCK monolayers (Fig. 5A). Importantly, this effect was blockable with L-fucose, demonstrating that LecB needs to bind to host cells to cause migration defects. Moreover, we established that the blockage of wound healing by LecB occurred in a dose-dependent manner, with concentrations larger than 50 $\mu\text{g/ml}$ completely blocking cell migration (Figs. 5B and 5C), whereas another fucose-binding lectin, UEA-I (50 $\mu\text{g/ml}$), did not induce suppression of wound healing (Fig. S5A). The inhibitory effect of LecB on wound healing was – as other LecB-mediated effects before – reversible by washing out LecB (Fig. S5B).

To explain the abrogation of cell migration by LecB we carried out live cell imaging experiments with MDCK cells stably expressing the plasma membrane marker ML-GFP (45). ML-GFP allowed visualizing lamellipodia formed by migrating MDCK cells (Fig. 5D, ctrl, white arrows). Interestingly, when cells were treated with LecB right after wounding, no lamellipodia formed (Fig. 5D, LecB), whereas washout of LecB was sufficient to reinstate lamellipodia formation and cell migration (Fig. S5C). When migrating cells were treated with LecB, lamellipodia ‘froze’ and LecB strongly bound to lamellipodia (Fig. S6). It is also interesting to note that cells deeper within the monolayer, which expose only their apical membranes to LecB in this assay, did still move (Fig. S6). In subsequent experiments we stained for $\beta 1$ -integrins in wound healing assays. This revealed that cells at the wound edge take up large amounts of LecB and in the same cells pronounced $\beta 1$ -integrin internalization was evident (Fig. 5E, white arrows), which can explain why these cells are not able to migrate any more.

Taken together, LecB inhibits epithelial wound healing in a reversible manner, which is presumably caused by the fact that integrins in wound edge cells are accessible by LecB and are internalized.

2.6 In dependence of LecB expression, *P. aeruginosa* is able to crawl underneath cells

The additional and probably dominant cytotoxic effects caused by the numerous toxins produced by *P. aeruginosa* prevented us from directly quantifying an effect of LecB knockdown in *in vitro* wound healing assays with live *P. aeruginosa*. However, we observed that *P. aeruginosa* (PAO1-wt) is able to crawl underneath exposed cells (Fig. 6A). We postulated that this requires at least local loosening of potentially integrin-mediated cell-substrate adhesion. We tested this hypothesis by investigating the influence of LecB on '*P. aeruginosa*-crawling'. To this end, we used a LecB-deficient PAO1 strain (PAO1-dLecB), which exhibited the same growth kinetics as PAO1-wt (Fig. S7A). After overnight culture the PAO1-wt strain showed clear expression of LecB, whereas the LecB-deficient *P. aeruginosa* (PAO1-dLecB) did not (Figs. S7B and S7C). In accordance with our hypothesis, PAO1-dLecB was visibly found less underneath cells (Fig. 6A). To substantiate the experimental procedure, we established that increasing the multiplicity of infection (MOI) (Figs. 6B and 6C) and increasing the duration of incubation (Figs. 6B and 6D) also increased the number of bacteria crawling underneath cells. Importantly, for all investigated conditions, the number of underneath-crawling bacteria per cell was lower for the PAO1-dLecB strain in comparison to the PAO1-wt strain.

In summary, our study reveals a novel mechanism in which LecB, through impairing cell-to-basement membrane attachment, allows for the creation of microniches enabling sub-epithelial colonization by *P. aeruginosa*.

3 Discussion

3.1 Integrins are major receptors of LecB

Lectins bind to carbohydrates and can therefore have multiple receptors that express the appropriate glycosylation. Hence it is interesting that our experiments suggest a favored binding of LecB to integrins. LecB binding to β 1-integrin appeared to be strong, because LecB was able to recover 75% of total β 1-integrin from cells when it was basolaterally applied and had only access to β 1-integrin at the cell surface.. As expected, LecB binding to β 1-integrin solely occurred through carbohydrates, since removal of β 1-integrin glycosylation abolished binding. Furthermore, mass spectrometry analysis of all basolateral LecB receptors revealed that virtually all integrins expressed by MDCK cells were among the top hits, including many integrin-associated proteins that were presumably recovered through co-precipitation with integrins.

This introduces LecB as new member to the list of bacterial molecules that bind integrins.

Another fucose binding lectin, UEA-I, was not able to mount any of the cellular effects that LecB caused. This shows that only binding to fucose is not sufficient and suggests that LecB has additional features that bring about its specific capabilities. First, LecB and UEA-I prefer different fucose linkages in oligosaccharides (UEA-I binds α _{1,2}-linked fucose but only weakly to α _{1,3}- and α _{1,6}-linked fucose (46, 47); LecB shows a slight preference for α _{1,4}-linked fucose, but also binds to α _{1,2}- and α _{1,3}-linked fucose (48–50)). In addition, LecB is a tetramer with four fucose binding sites, but UEA-1 is a dimer offering only two binding sites (35).

It is also worth to note that the sequence of LecB varies slightly between different strains of *P. aeruginosa* (51, 52). Since ligand binding among LecB variants is conserved, we expect that these LecB variants are utilized in similar ways as we reported here for LecB in the *P. aeruginosa* strain PAO1.

3.2 Mechanism of LecB-mediated integrin internalization

Since LecB recognizes only the carbohydrate moieties of integrins, it is able to manipulate integrins via unique mechanisms. The structure of LecB with four opposing binding sites is ideal to crosslink receptors. This has been demonstrated before *in vitro* by showing that LecB is able to crosslink GUVs that contain LecB receptors (53).

We hypothesize that the crosslinking capacity of LecB is key for the observed rapid internalization of integrins. In addition to integrins, LecB was also able to recognize fucose-bearing glycosphingolipids and to cause membrane invaginations without the need of additional energy input, which replicates effects caused by other glycosphingolipid-binding lectins like StxB (42), CtxB (54), or RSL (55). In addition, β 1-integrin was also found on LecB-generated membrane invaginations on energy-depleted cells. This suggests that LecB causes on the one hand membrane invaginations and on the other hand is able to recruit integrins to these invaginations, thus constituting a potent endocytic mechanism. A similar mechanism was suggested for the host cell-endogenous protein galectin-3 (40). This means that bacteria have evolved molecules like LecB that can hijack this endogenous uptake route. Importantly, LecB-mediated lipid-integrin-crosslinking for internalization represents a mechanism that can explain the observed integrin internalization that occurred regardless of integrin activation status and carried also basement membrane ligands like laminins with it.

3.3 *LecB-triggered inhibition of wound healing*

LecB binding to basolateral cell surfaces caused cellular effects that could be causally linked to integrin internalization. In fully polarized epithelial cells, binding of LecB to basolateral cell surfaces, but not to apical cell surfaces, which do not contain significant amounts of integrins, led to loss of apico-basal polarity. This indicates the need of integrin internalization for dissolution of polarity. In addition, loss of polarity was reversible after washout of LecB and coincided well with the return of $\beta 1$ -integrin to the basolateral plasma membrane.

Our data also suggest that LecB-mediated integrin internalization is responsible for the observed block in cell migration in epithelial wound healing assays. First, integrins were preferentially internalized in wound edge cells and LecB prominently bound to lamellipodia in edge cells. This makes sense, since edge cells offer more cellular surface area for LecB binding and expose their integrins in contrast to cells deeper within the intact monolayer, which display only their apical surfaces to LecB. Second, edge cells rapidly and efficiently stopped moving upon LecB treatment, whereas other cells deeper within the monolayer preserved their capacity to move within the monolayer.

Diminished healing of *P. aeruginosa*-infected wounds was reported previously (10). However, *P. aeruginosa* possesses multiple mechanisms to manipulate and to intoxicate host cells. We therefore anticipate that, in order to inhibit wound healing, *P. aeruginosa* will apply different combinations of its arsenal, including LecB-mediated inhibition of cell migration, in dependence of the host tissue (25).

3.4 *LecB has a role in enabling bacteria to crawl underneath host cells*

Our experiments revealed a novel feature of *P. aeruginosa* behavior: We observed that bacteria frequently crawled underneath host cells. For this, at least local loosening of cell-substrate adhesion is required, which could be achieved by LecB-mediated integrin internalization. We therefore investigated the contribution of LecB to underneath-cell-crawling of the *P. aeruginosa* strain PAO1. Indeed, knocking out LecB significantly decreased crawling events. Based on our results, we suggest that *P. aeruginosa* uses LecB to manipulate integrin-basement membrane interaction to proceed along the interface between epithelial cells and the basement membrane.

In summary, our work brings integrins into focus as target of *P. aeruginosa* and provides additional rationales for the ongoing efforts to develop LecB inhibitors as additional treatment strategy to antibiotics (26–31).

4 Materials and Methods

4.1 Antibodies, plasmids and reagents

Used antibodies are listed in Table S2. The plasmid pPH-Akt-GFP encoding PH-Akt - GFP was a gift from Tamas Balla (Addgene plasmid # 51465). The plasmid encoding GFP tagged with a glycosylphosphatidylinositol (GPI) anchor (pGPI-GFP) was described before (56). The plasmid encoding for GFP tagged with a Lyn-derived myristoylation motif (pML-GFP) was a gift from Christian Wunder (Curie Institute, Paris, France).

Recombinant LecB was produced in *Escherichia coli* BL21(DE3) cells and purified with affinity columns as previously described (41). LecB and fluorophore-conjugated LecB were used at a concentration of 50 µg/ml (4.3 µM) unless stated otherwise. UEA-I and UEA-I-FITC were from Vector Labs. Cycloheximide, and L-fucose (6-Deoxy-L-galactose) were from Sigma Aldrich.

4.2 Mammalian cell culture, creation of stable cell lines

MDCK strain II cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 5% fetal calf serum (FCS) at 37 °C and 5% CO₂. Unless stated otherwise 3×10⁵ MDCK cells were seeded per transwell filter (0.4 µm pore size, polycarbonate membrane, #3401 from Corning) and cultured for 4 d before experiments. For the creation of stable MDCK cell lines plasmids encoding the proteins of interest and G418 resistance (pPH-Akt-GFP, pML-GFP, and pGPI-GFP) were transfected into cells with Lipofectamine 2000 (Thermo Fisher). After allowing the cells to express the proteins overnight, they were trypsinized and plated sparsely in medium containing 1 mg/ml G418. After single colonies had formed, GFP-positive colonies were extracted with cloning rings. At least 6 colonies were extracted for each

cell line, grown on transwell filters for 4 d, fixed and stained against the basolateral marker protein β -catenin and the tight junction marker protein ZO-1 to assay their polarized morphology. Based on these results we chose one colony for each cell line for further experiments. TEER measurements were carried out using an EVOM2 equipped with chopstick electrodes (World Precision Instruments).

4.3 Immunofluorescence

Cells were washed two times with phosphate-buffered saline without Ca^{2+} and Mg^{2+} (PBS), and then fixed with 4% (w/v) formaldehyde (FA) for 15 min at room temperature. Samples were treated with 50 mM ammonium chloride for 5 min to quench FA and then permeabilized with a SAPO medium (PBS supplemented with 0.2% (w/v) bovine serum albumin and 0.02% (w/v) saponin) for 30 min. Primary antibodies were diluted in SAPO medium and applied on the samples for 60 min at room temperature. After three washes with PBS, secondary dye-labeled antibodies, and, if required, DAPI and dye-labeled phalloidin, were diluted in SAPO medium and applied to the cells for 30 min at room temperature (details for the used antibodies are listed in Table S2). After 5 washes with PBS cells were mounted for microscopy. Since $\alpha 3$ -integrin antibodies did not work in FA-fixed cells, methanol fixation was applied in this case. Briefly, cells were incubated with pre-cooled methanol for 15 min at -20°C . After washing with PBS, cells were permeabilized with 0.05% (v/v) Triton X-100 for 10 min at room temperature and blocked with 3% (w/v) bovine serum albumin (BSA) for 1 h at room temperature. Staining with primary and secondary antibodies was then carried out as described before, but with a 3% (w/v) BSA solution.

4.4 Microscopic imaging of fixed cells and live cell experiments

For microscopic imaging an A1R confocal microscope (Nikon) equipped with a 60x oil immersion objective (NA = 1.49) and laser lines at 405 nm, 488 nm, 561 nm, and 641 nm was utilized. Image acquisition and analysis was performed with NIS-Elements 4.10.04 (Nikon).

Live cell experiments were carried out at 37°C and MDCK cells grown as polarized monolayers for 3 d on Lab-Tek II chambered cover glasses (8 well, 1.5 borosilicate glass) were used. The medium was changed to recording medium (Hank's balanced salt solution (HBSS) supplemented with 1% FCS, 4.5 g/L glucose, and 20 mM HEPES).

4.5 Wound healing assays

MDCK cells were seeded on 12 well plates or, for live cell microscopy of cell migration, on 8 well Lab-Tek II chambered cover glasses and allowed to form confluent monolayers for 3 d. Then cells were scratched with a 200 µl-pipet tip to inflict a wound. On 12 well plates, marker lines were drawn on the bottom to ensure that always the same position of the wound was imaged.

4.6 Western blot analysis

Cells were washed twice with PBS and lysed in RIPA buffer (20 mM Tris (pH 8), 0.1% (w/v) SDS, 10% (v/v) glycerol, 13.7 mM NaCl, 2mM EDTA, and 0.5% (w/v) sodium deoxycholate in water), supplemented with protease inhibitors (0.8 µM aprotinin, 11 µM leupeptin, 200 µM pefabloc) and phosphatase inhibitor (1 mM sodium orthovanadate). Protein concentrations were analyzed using a BCA assay kit (Pierce). Equal amounts of protein per lysate were separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked with tris-buffered saline (TBS) supplemented with 0.1% (v/v) Tween 20 and 3% (w/v) BSA for one hour and incubated

with primary and HRP-linked secondary antibodies diluted in the blocking solution. In some cases, TBS supplemented with 0.1% (v/v) Tween 20 and 5% (w/v) milk powder was used (details for the used antibodies and conditions are listed in Table S2). Detection was performed by a chemiluminescence reaction using the Fusion-FX7 Advance imaging system (Peqlab Biotechnologie GmbH).

4.7 Energy depletion

Energy depletion was carried out as described before (42). Briefly, MDCK cells were washed 2 times with PBS supplemented with 100 mg/l CaCl_2 and 100 mg/l $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ (PBS++) and then treated with PBS++ supplemented with 10 mM 2-deoxy-D-glucose and 10mM NaN_3 for 30 min at 37 °C.

4.8 Bacteria culture and crawling experiments

GFP-tagged *P. aeruginosa* PAO1 wild type (PAO1-wt) and LecB-deficient (PAO1-dLecB) strains were provided by S. de Bentzmann (CNRS - Aix Marseille University, France). The generation of LecB-deficient PAO1 is described in (23) and GFP-tagging was carried out according to the procedure described in (57). For experiments, bacteria were cultured overnight (approximately 16 h) in LB-Miller medium containing 60 µg/ml gentamicin in a shaker (Thriller, Peqlab) at 37 °C and 650 rpm. The bacteria reached an OD measured at 600 nm of approximately 5. Using these growth conditions, PAO1-wt and PAO1-dLecB strains showed comparable growth kinetics (Fig. S7A) and harvested PAO1-wt efficiently expressed LecB, whereas PAO1-dLecB did not (Figs. S7B and S7C).

For crawling experiments MDCK cells were sparsely seeded on 8 well Lab-Tek II chambered cover glasses and cultured for 1 d, so that clusters with maximally 10 cells

in diameter formed to ensure that all cells were exposed to *P. aeruginosa* similar as at a wound edge. Then, PAO1-wt or PAO-dLecB were applied for the indicated MOI and duration. Bacteria crawling under cells were counted manually per cell from confocal image stacks of whole cells to ensure that only bacteria located directly underneath cells at the level of the glass cover slip were counted.

4.9 qPCR

PAO1-wt and PAO1-dLecB were cultured overnight as described before. RNA was extracted using TRI reagent (Sigma Aldrich). After DNase digest, 100 ng RNA was transcribed into cDNA using a first strand cDNA synthesis kit (Thermo Fisher). Then qPCR was performed on a CFX384 qPCR cycler (Bio-Rad) using a SYBR Select master mix (Thermo Fisher) and the following primers: for LecB: forward: 3'-AAGGAGTGTTACCCCTTCCC-5', reverse: 3'-GATGACGGCGTTATTGGTGC-5'; for rpoD as reference: forward: 3'-GGGATACCTGACTTACGCGG-5', reverse: 3'-GGGGCTGTCTCGAATACGTT-5'.

4.10 Labeling of lectins

LecB was labeled with fluorescent dyes bearing NHS esters as reactive groups (Cy3 mono-reactive NHS ester (GE Healthcare), Cy5 mono-reactive NHS ester (GE Healthcare), Alexa488 NHS ester (Thermo Fisher)) or with biotin using NHS-PEG12-biotin (Thermo Fisher) according to the instructions of the manufacturers and purified using PD-10 desalting columns (GE Healthcare).

4.11 Cell surface biotinylation and immunoprecipitation

For cell surface biotinylation, all following steps were carried out in a cold room (4 °C). Sulfo-NHS-biotin (Thermo Fisher) was freshly diluted in PBS++ (concentration 0.3 mg/ml) and applied to the apical or basolateral plasma membrane of transwell filter grown MDCK cells for 20 min. Afterwards, the reaction was quenched for 20 min with PBS++ supplemented with 50 mM ammonium chloride. Cells were lysed with RIPA buffer and biotinylated proteins were precipitated with streptavidin-agarose beads (Thermo Fisher). Elution was carried out with Laemmli buffer (2% (w/v) SDS, 10% (v/v) glycerol, 60 mM Tris-Cl (pH 6.8) in water) and boiling at 98 °C for 5 min.

For β 1-integrin IP, MDCK cells were grown to confluence in 10 cm dishes and lysed in IP lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM sodium chloride, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) sodium deoxycholate in water). The lysates were pre-cleared with protein A-agarose beads (Roche) for 3 h and then incubated with anti- β 1-integrin antibodies (MAB2000 from Millipore) for 1 h. After adding of protein A-agarose beads overnight, beads were washed three times with IP-lysis buffer, and β 1-integrin was eluted with Laemmli buffer and boiling at 98 °C for 5 min.

4.12 Mass spectrometry-based identification of LecB interaction partners

MDCK cells were cultured in SILAC media for 9 passages and then seeded on transwell filters and allowed to polarize for 4 d. For the first sample, biotinylated LecB was applied to the apical side of light-SILAC-labeled cells and on the basolateral side of medium-SILAC-labeled cells, whereas heavy-SILAC-labeled cells received no stimulation and served as control. For the second sample, the treatment conditions were permuted. After lysis with IP lysis buffer, the different SILAC lysates were combined and LecB-biotin-receptor complexes were precipitated using streptavidin agarose beads as described before. Eluted LecB-biotin-receptor complexes were then prepared for MS

analysis using SDS-PAGE gel electrophoresis. Gels were cut into pieces, proteins therein digested with trypsin and resulting peptides were purified by STAGE tips. For mass spectrometry analysis, samples were fractionated by nanoscale HPLC on a 1200 HPLC (Agilent Technologies, Waldbronn, Germany) connected online to a LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Fused silica HPLC-column tips with 75 µm inner diameter were self-packed with Reprosil–Pur 120 ODS–3 (Dr. Maisch, Ammerbuch, Germany) to a length of 20 cm. Samples were directly injected into the mass spectrometer. For details see reference #58. The raw data files were uploaded into the MaxQuant software. Database searches were performed against a full-length dog database containing common contaminants such as keratins and enzymes used for in–gel digestion. Carbamidomethylcysteine was set as fixed modification, oxidation of methionine and protein amino–terminal acetylation was set as variable modifications. Triple SILAC was used as quantitation mode. The enzyme specificity was trypsin/P+DP with three allowed miss cleavages. The MS/MS tolerance was set to 0.5 Da and the mass precision of identified peptides after recalibration was in general less than 1 ppm. For identification and quantitation, the following settings were used: peptide and protein FDR were set to 0.01, maximum peptide posterior error probability (PEP) was set to 0.1, minimum peptide length was set to 7, minimum number peptides for identification and quantitation of proteins was set to two of which one must be unique, minimum ratio count was set to two, and only unmodified peptides and the variable modification were used for protein quantification. The “match between run” option was used with a time window of 2 min. From the generated list of MS-identified proteins we defined those proteins as LecB interaction partners that showed more than 2-fold enrichment on a log₂-scale over controls in both SILAC samples (see Table S1).

555

556 *4.13 GUV experiments*

557 Giant unilamellar vesicles (GUVs) were composed of DOPC, spiked with 1 mol%
 558 BODIPY-FL-C₅-HPC, 30 mol% cholesterol, and 5 mol% of the desired
 559 glycosphingolipid species. Blood group glycosphingolipids were provided by Göran
 560 Larson (Sahlgrenska University Hospital, Gothenburg, Sweden). GUVs were grown at
 561 room temperature using the electroformation technique on indium-tin oxide (ITO)-
 562 coated slides as described previously (42, 43). Briefly, lipid mixtures were dissolved in
 563 chloroform at a final concentration of 0.5 mg/ml, and 15 µl solution was spread on the
 564 conductive surface of ITO slides. After 2 h of drying under vacuum, GUVs were grown
 565 in a 290 mosM sucrose solution by applying an alternating electric field from 20 mV
 566 to 1.1 V for 3 h.

567 LecB-Cy3 (15 µg/ml) was incubated with GUVs at room temperature and examined
 568 under an inverted confocal fluorescence microscope (Nikon A1R) equipped with an oil
 569 immersion objective (60x, NA 1.49).

570

571 *4.14 Statistics*

572 If not stated otherwise data obtained from n = 3 independent experiments were used to
 573 calculate arithmetic means. Error bars represent standard error mean (SEM). Statistical
 574 significance analysis was carried out using GraphPad Prism 5.

575

576 **5 Acknowledgements**

577 This work was supported by a German Research Foundation grant [RO 4341/2-1], the
578 Excellence Initiative of the German Research Foundation [EXC 294], the Ministry of
579 Science, Research and the Arts of Baden-Württemberg [Az: 33-7532.20], and a starting
580 grant from the European Research Council [Programme “Ideas,” ERC-2011-StG
581 282105]. R.T. acknowledges support from the Ministry of Science, Research and the
582 Arts of Baden-Württemberg [Az: 7533-30-10/25/36].

6 References

1. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. *Clin Microbiol Rev* 15:194–222.
2. Franzetti F, Grassini A, Piazza M, Degl’Innocenti M, Bandera A, Gazzola L, Marchetti G, Gori A. 2006. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. *Infection* 34:9–16.
3. Markou P, Apidianakis Y. 2014. Pathogenesis of intestinal *Pseudomonas aeruginosa* infection in patients with cancer. *Front Cell Infect Microbiol* 3:115.
4. Barbier F, Andremont A, Wolff M, Bouadma L. 2013. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. *Curr Opin Pulm Med* 19:216–228.
5. Azzopardi EA, Azzopardi E, Camilleri L, Villapalos J, Boyce DE, Dziwulski P, Dickson WA, Whitaker IS. 2014. Gram negative wound infection in hospitalised adult burn patients-systematic review and metanalysis. *PLoS One* 9:e95042.
6. Stover C, Pham X, Erwin A, Mizoguchi S, Warrenner P, Hickey M, Brinkman F, Hufnagle W, Kowalik D, Lagrou M, Garber R, Goltry L, Tolentino E, Westbrook-Wadman S, Yuan Y, Brody L, Coulter S, Folger K, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong G, Wu Z, Paulsen I, Reizer J, Saier M, Hancock R, Lory S, Olson M. 2000. Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature* 406:959–964.
7. Maillet M, Pelloux I, Forli A, Vancoetsem K, Cheong Sing JS, Marfaing S, Ducki S, Batailler P, Mallaret M-R. 2014. Nosocomial transmission of

- 608 carbapenem-resistant *Pseudomonas aeruginosa* among burn patients. *Infect*
609 *Control Hosp Epidemiol* 35:597–599.
- 610 8. Kinsey CB, Koirala S, Solomon B, Rosenberg J, Robinson BF, Neri A, Halpin
611 AL, Arduino MJ, Moulton-Meissner H, Noble-Wang J, others. 2017.
612 *Pseudomonas aeruginosa* Outbreak in a Neonatal Intensive Care Unit
613 Attributed to Hospital Tap Water. *Infect Control Hosp Epidemiol* 38:801–808.
- 614 9. Mah T-F, Pitts B, Pellock B, Walker GC, Stewart PS, O’Toole GA. 2003. A
615 genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature*
616 426:306.
- 617 10. Engel J, Eran Y. 2011. Subversion of mucosal barrier polarity by *Pseudomonas*
618 *aeruginosa*. *Front Microbiol* 2:1–7.
- 619 11. WHO. 2017. WHO priority pathogens list for research and development of new
620 antibiotics.
- 621 12. Wagner S, Sommer R, Hinsberger S, Lu C, Hartmann RW, Empting M, Titz A.
622 2016. Novel Strategies for the Treatment of *Pseudomonas aeruginosa*
623 Infections. *J Med Chem* 59:5929–5969.
- 624 13. Golovkine G, Faudry E, Bouillot S, Elsen S, Attrée I, Huber P. 2016.
625 *Pseudomonas aeruginosa* transmigrates at epithelial cell-cell junctions,
626 exploiting sites of cell division and senescent cell extrusion. *PLoS Pathog*
627 12:e1005377.
- 628 14. Tran CS, Eran Y, Ruch TR, Bryant DM, Datta A, Brakeman P, Kierbel A,
629 Wittmann T, Metzger RJ, Mostov KE, Engel JN. 2014. Host cell polarity
630 proteins participate in innate immunity to *Pseudomonas aeruginosa* infection.
631 *Cell Host Microbe* 15:636–43.
- 632 15. Kwok T, Zabler D, Urman S, Rohde M, Hartig R, Wessler S, Misselwitz R,

- 633 Berger J, Sewald N, Konig W, Backert S. 2007. Helicobacter exploits integrin
634 for type IV secretion and kinase activation. Nature 449:862–866.
- 635 16. Stewart PL, Nemerow GR. 2007. Cell integrins: commonly used receptors for
636 diverse viral pathogens. Trends Microbiol 15:500–507.
- 637 17. Cossart P. 1997. Host/pathogen interactions. Subversion of the mammalian cell
638 cytoskeleton by invasive bacteria. J Clin Invest 99:2307–2311.
- 639 18. Roger P, Puchelle E, Bajolet-Laudinat O, Tournier J-M, Debordeaux C,
640 Plotkowski M-C, Cohen JHM, Sheppard D, De Bentzmann S. 1999.
641 Fibronectin and $\alpha 5 \beta 1$ integrin mediate binding of Pseudomonas aeruginosa to
642 repairing airway epithelium. Eur Respir J 13:1301–1309.
- 643 19. Leroy-Dudal J, Gagnière H, Cossard E, Carreiras F, Di Martino P. 2004. Role
644 of $\alpha v \beta 5$ integrins and vitronectin in Pseudomonas aeruginosa PAK interaction
645 with A549 respiratory cells. Microbes Infect 6:875–881.
- 646 20. Imberty A, Wimmerová M, Mitchell EP, Gilboa-Garber N. 2004. Structures of
647 the lectins from Pseudomonas aeruginosa: Insights into the molecular basis for
648 host glycan recognition. Microbes Infect 6:221–228.
- 649 21. Tielker D, Hacker S, Loris R, Strathmann M, Wingender J, Wilhelm S,
650 Rosenau F, Jaeger KE. 2005. Pseudomonas aeruginosa lectin LecB is located
651 in the outer membrane and is involved in biofilm formation. Microbiology
652 151:1313–1323.
- 653 22. Funken H, Bartels KM, Wilhelm S, Brocker M, Bott M, Bains M, Hancock
654 REW, Rosenau F, Jaeger KE. 2012. Specific Association of Lectin LecB with
655 the Surface of Pseudomonas aeruginosa: Role of Outer Membrane Protein
656 OprF. PLoS One 7:1–8.
- 657 23. Chemani C, Imberty A, De Bentzmann S, Pierre M, Wimmerová M, Guery BP,

- 658 Faure K. 2009. Role of LecA and LecB lectins in *Pseudomonas aeruginosa*-
659 induced lung injury and effect of carbohydrate ligands. *Infect Immun* 77:2065–
660 2075.
- 661 24. Adam EC, Mitchell BS, Schumacher DU, Grant G, Schumacher U. 1997.
662 *Pseudomonas aeruginosa* II lectin stops human ciliary beating: Therapeutic
663 implications of fucose. *Am J Respir Crit Care Med* 155:2102–2104.
- 664 25. Cott C, Thuenauer R, Landi A, Kühn K, Juillot S, Imberty A, Madl J, Eierhoff
665 T, Römer W. 2016. *Pseudomonas aeruginosa* lectin LecB inhibits tissue repair
666 processes by triggering β -catenin degradation. *Biochim Biophys Acta (BBA)-*
667 *Molecular Cell Res* 1863:1106–1118.
- 668 26. Sommer R, Wagner S, Rox K, Varrot A, Hauck D, Wamhoff E-C, Schreiber J,
669 Ryckmans T, Brunner T, Rademacher C, others. 2018. Glycomimetic, orally
670 bioavailable LecB inhibitors block biofilm formation of *Pseudomonas*
671 *aeruginosa*. *J Am Chem Soc* 140:2537–2545.
- 672 27. Sommer R, Hauck D, Varrot A, Wagner S, Audfray A, Prestel A, Möller HM,
673 Imberty A, Titz A. 2015. Cinnamide Derivatives of d-Mannose as Inhibitors of
674 the Bacterial Virulence Factor LecB from *Pseudomonas aeruginosa*.
675 *ChemistryOpen* 4:756–767.
- 676 28. Johansson EM V, Crusz SA, Kolomiets E, Buts L, Kadam RU, Cacciarini M,
677 Bartels K-M, Diggle SP, Cámara M, Williams P, others. 2008. Inhibition and
678 dispersion of *Pseudomonas aeruginosa* biofilms by glycopeptide dendrimers
679 targeting the fucose-specific lectin LecB. *Chem Biol* 15:1249–1257.
- 680 29. Donnier-Marechal M, Abdullayev S, Bauduin M, Pascal Y, Fu M-Q, He X-P,
681 Gillon E, Imberty A, Kipnis E, Dessein R, Vidal S. 2018. Tetraphenylethylene-
682 based glycoclusters with aggregation-induced emission (AIE) properties as

- 683 high-affinity ligands of bacterial lectins. *Org Biomol Chem* 16:8804–8809.
- 684 30. Bucher KS, Babic N, Freichel T, Kovacic F, Hartmann L. 2018. Monodisperse
685 Sequence-Controlled alpha-l-Fucosylated Glycooligomers and Their
686 Multivalent Inhibitory Effects on LecB. *Macromol Biosci* e1800337.
- 687 31. Dupin L, Noel M, Bonnet S, Meyer A, Gehin T, Bastide L, Randrianntsoa M,
688 Souteyrand E, Cottin C, Vergoten G, Vasseur J-J, Morvan F, Chevolot Y,
689 Darblade B. 2018. Screening of a library of oligosaccharides targeting lectin
690 LecB of *Pseudomonas aeruginosa* and synthesis of high affinity
691 oligoglycoclusters. *Molecules* 23.
- 692 32. Rodriguez-Boulan E, Kreitzer G, Müsch A. 2005. Organization of vesicular
693 trafficking in epithelia. *Nat Rev Mol Cell Biol* 6:233–247.
- 694 33. Thuenauer R, Hsu YC, Carvajal-Gonzalez JM, Deborde S, Chuang J, Römer
695 W, Sonnleitner A, Rodriguez-Boulan E, Sung C. 2014. Four-dimensional live
696 imaging of apical biosynthetic trafficking reveals a post-Golgi sorting role of
697 apical endosomal intermediates. *Proc Natl Acad Sci U S A* 111:4127–32.
- 698 34. Kierbel A, Gassama-Diagne A, Rocha C, Radoshevich L, Olson J, Mostov K,
699 Engel J. 2007. *Pseudomonas aeruginosa* exploits a PIP3-dependent pathway to
700 transform apical into basolateral membrane. *J Cell Biol* 177:21–27.
- 701 35. Audette GF, Vandonselaar M, Delbaere LTJ. 2000. The 2.2 Å resolution
702 structure of the O (H) blood-group-specific lectin I from *Ulex europaeus*. *J Mol*
703 *Biol* 304:423–433.
- 704 36. Myllymäki SM, Teräväinen TP, Manninen A. 2011. Two distinct integrin-
705 mediated mechanisms contribute to apical lumen formation in Epithelial cells.
706 *PLoS One* 6.
- 707 37. Greciano PG, Moyano J V, Buschmann MM, Tang J, Lu Y, Rudnicki J,

708 Manninen A, Matlin KS. 2012. Laminin 511 partners with laminin 332 to
709 mediate directional migration of Madin-Darby canine kidney epithelial cells.
710 Mol Biol Cell 23:121–136.

711 38. Le Bivic A, Sambuy Y, Mostov K, Rodriguez-Boulan E. 1990. Vectorial
712 targeting of an endogenous apical membrane sialoglycoprotein and uvomorulin
713 in MDCK cells. J Cell Biol 110:1533–1539.

714 39. Furtak V, Hatcher F, Ochieng J. 2001. Galectin-3 mediates the endocytosis of
715 β -1 integrins by breast carcinoma cells. Biochem Biophys Res Commun
716 289:845–850.

717 40. Lakshminarayan R, Wunder C, Becken U, Howes MT, Benzing C, Arumugam
718 S, Sales S, Ariotti N, Chambon V, Lamaze C, others. 2014. Galectin-3 drives
719 glycosphingolipid-dependent biogenesis of clathrin-independent carriers. Nat
720 Cell Biol 16:592.

721 41. Mitchell EP, Sabin C, Šnajdrová L, Pokorná M, Perret S, Gautier C, Hofr C,
722 Gilboa-Garber N, Koča J, Wimmerová M, Imberty A. 2005. High affinity
723 fucose binding of *Pseudomonas aeruginosa* lectin PA-IIL: 1.0 Å resolution
724 crystal structure of the complex combined with thermodynamics and
725 computational chemistry approaches. Proteins Struct Funct Genet 58:735–746.

726 42. Römer W, Berland L, Chambon V, Gaus K, Windschiegl B, Tenza D, Aly
727 MRE, Fraisier V, Florent J-C, Perrais D, Lamaze C, Raposo G, Steinem C,
728 Sens P, Bassereau P, Johannes L. 2007. Shiga toxin induces tubular membrane
729 invaginations for its uptake into cells. Nature 450:670–675.

730 43. Römer W, Pontani LL, Sorre B, Rentero C, Berland L, Chambon V, Lamaze C,
731 Bassereau P, Sykes C, Gaus K, Johannes L. 2010. Actin Dynamics Drive
732 Membrane Reorganization and Scission in Clathrin-Independent Endocytosis.

- 733 Cell 140:540–553.
- 734 44. Wood S, Sivaramakrishnan G, Engel J, Shafikhani SH. 2011. Cell migration
735 regulates the kinetics of cytokinesis. *Cell Cycle* 10:648–654.
- 736 45. Thuenauer R, Nicklaus S, Frensch M, Troendle K, Madl J, Römer W. 2018. A
737 microfluidic biochip for locally confined stimulation of cells within an
738 epithelial monolayer. *RSC Adv* 8:7839–7846.
- 739 46. Baldus SE, Thiele J, Park Y-O, Hanisch F-G, Bara J, Fischer R. 1996.
740 Characterization of the binding specificity of *Anguilla anguilla* agglutinin
741 (AAA) in comparison to *Ulex europaeus* agglutinin I (UEA-I). *Glycoconj J*
742 13:585–590.
- 743 47. Sughii S, Kabat E, HH B. 1982. Further immunochemical studies on the
744 combining sites of *Lotus tetragonolobus* and *Ulex europaeus* I and II lectins.
745 *Carbohydr Res* 99:99–101.
- 746 48. Marotte K, Sabin C, Prville C, Moumé-Pymbock M, Wimmerová M, Mitchell
747 EP, Imberty A, Roy R. 2007. X-ray structures and thermodynamics of the
748 interaction of PA-IIL from *Pseudomonas aeruginosa* with disaccharide
749 derivatives. *ChemMedChem* 2:1328–1338.
- 750 49. Perret S, Sabin C, Dumon C, Pokorná M, Gautier C, Galanina O, Ilia S, Bovin
751 N, Nicaise M, Desmadril M, others. 2005. Structural basis for the interaction
752 between human milk oligosaccharides and the bacterial lectin PA-IIL of
753 *Pseudomonas aeruginosa*. *Biochem J* 389:325–332.
- 754 50. Mitchell E, Houles C, Sudakevitz D, Wimmerova M, Gautier C, Pérez S, Wu
755 AM, Gilboa-Garber N, Imberty A. 2002. Structural basis for oligosaccharide-
756 mediated adhesion of *Pseudomonas aeruginosa* in the lungs of cystic fibrosis
757 patients. *Nat Struct Mol Biol* 9:918.

- 758 51. Boukerb AM, Decor A, Ribun S, Tabaroni R, Rousset A, Commin L, Buff S,
759 Doleans-Jordheim A, Vidal S, Varrot A, Imberty A, Cournoyer B. 2016.
760 Genomic Rearrangements and Functional Diversification of lecA and lecB
761 Lectin-Coding Regions Impacting the Efficacy of Glycomimetics Directed
762 against *Pseudomonas aeruginosa*. *Front Microbiol* 7:811.
- 763 52. Sommer R, Wagner S, Varrot A, Nycholat CM, Khaledi A, Haussler S,
764 Paulson JC, Imberty A, Titz A. 2016. The virulence factor LecB varies in
765 clinical isolates: consequences for ligand binding and drug discovery. *Chem*
766 *Sci* 7:4990–5001.
- 767 53. Villringer S, Madl J, Sych T, Manner C, Imberty A, Römer W. 2018. Lectin-
768 mediated protocell crosslinking to mimic cell-cell junctions and adhesion. *Sci*
769 *Rep* 8:1932.
- 770 54. Ewers H, Römer W, Smith AE, Bacia K, Dmitrieff S, Chai W, Mancini R,
771 Kartenbeck J, Chambon V, Berland L, Oppenheim A, Schwarzmann G, Feizi
772 T, Schwille P, Sens P, Helenius A, Johannes L. 2010. GM1 structure
773 determines SV40-induced membrane invagination and infection. *Nat Cell Biol*
774 12:11–18; sup pp 1-12.
- 775 55. Arnaud J, Tröndle K, Claudinon J, Audfray A, Varrot A, Römer W, Imberty A.
776 2014. Membrane deformation by neolectins with engineered glycolipid binding
777 sites. *Angew Chemie - Int Ed* 53:9267–9270.
- 778 56. Thuenauer R, Juhasz K, Mayr R, Frühwirth T, Lipp A-M, Balogi Z,
779 Sonnleitner A. 2011. A PDMS-based biochip with integrated sub-micrometre
780 position control for TIRF microscopy of the apical cell membrane. *Lab Chip*
781 11:3064–3071.
- 782 57. Eierhoff T, Bastian B, Thuenauer R, Madl J, Audfray A, Aigal S, Juillot S,

783 Rydell GE, Müller S, de Bentzmann S, Imberty A, Fleck C, Römer W. 2014. A
784 lipid zipper triggers bacterial invasion. *Proc Natl Acad Sci U S A* 111:6–11.
785 58. Thriene K, Gruning BA, Bornert O, Erxleben A, Leppert J, Athanasiou I,
786 Weber E, Kiritsi D, Nystrom A, Reinheckel T, Backofen R, Has C, Bruckner-
787 Tuderman L, Dengjel J. 2018. Combinatorial Omics Analysis Reveals
788 Perturbed Lysosomal Homeostasis in Collagen VII-deficient Keratinocytes.
789 *Mol Cell Proteomics* 17:565–579.
790

7 Figures and Figure Legends

Fig. 1: Basolateral LecB application depolarized MDCK cells and caused integrin internalization

(A) Polarized, filter-grown MDCK cells stably expressing the apical marker GPI-GFP (green) were left untreated (ctrl) or treated apically (AP) or basolaterally (BL) with 50 μ g/ml LecB for the indicated time periods, fixed and stained with antibodies recognizing the basolateral marker β -catenin (red) and the tight junction marker ZO-1 (white), nuclei were stained with DAPI (blue). Representative sections along the apico-basal axis (x-z sections) extracted from confocal image stacks are shown. (B) Time course of the trans-epithelial electrical resistance (TEER) of MDCK monolayers treated AP or BL with LecB. The mean values from n = 3 experiments are displayed. (C) LecB

803 was applied BL to MDCK cells stably expressing PH-Akt-GFP (green) for the indicated
804 time periods. Cells were fixed and stained for β 1-integrin (red); nuclei were stained
805 with DAPI (blue). Representative x-z sections extracted from confocal image stacks are
806 depicted. (D) MDCK cells were treated with LecB as indicated, fixed, and stained for
807 β 1-integrin (red) and β -catenin (green). Maximum intensity projections of confocal
808 image stacks covering total cell heights are shown. (E) The time course of the TEER of
809 MDCK cells treated BL with LecB as indicated and after washout was measured.

Figure 2: LecB directly binds to β1-integrin

(A) LecB-biotin was applied apically (AP) or basolaterally (BL) to polarized filter grown MDCK cells or cells were mock-treated AP or BL. Cells were lysed and LecB-biotin-receptor complexes were precipitated with streptavidin beads. Afterwards the presence of β1-integrin was probed by Western blot in the precipitate and the remaining supernatant of the precipitation. (B) LecB-Cy3 (red) was applied basolaterally to MDCK cells for 6 h. Cells were fixed and stained for β1-integrin (green). A confocal section (x-y section) crossing the cells in the sub-apical region is displayed, since in this region most internalized vesicles were concentrated. (C) MDCK cells were lysed, β1-integrins were immunoprecipitated and treated or left untreated with PNGase F to remove N-linked glycans. Western blot analysis of the immunoprecipitated β1-integrins was performed and β1-integrin presence was proven by staining with anti-β1-integrin antibodies (white arrows). Also bands from the antibody used for β1-integrin precipitation are visible (white arrowheads) and proteins that putatively co-precipitated with β1-integrin (blue arrows). To probe the binding of LecB to β1-integrin, LecB-Cy5 was incubated with membranes (far Western assay).

Figure 3: LecB internalizes $\alpha 3\beta 1$ -integrin regardless of its activation status and together with laminins

(A) MDCK cells were treated with LecB as indicated, fixed with methanol, and stained for $\alpha 3$ -integrin (red) and $\beta 1$ -integrin (green). Confocal sections (x-y sections) through the middle of the cells extracted from confocal image stacks are shown. (B) MDCK cells were treated with LecB-Cy3 (red) as indicated, fixed, and stained for pan-laminin (green), and $\beta 1$ -integrin (magenta); nuclei were stained with DAPI (blue); x-y confocal sections through the middle of the cells are depicted. (C) – (E) MDCK cells were treated with LecB as indicated and surface biotinylation from the basolateral side was performed. After precipitation of biotinylated proteins, the precipitates representing the surface fraction (S) and the supernatant representing the intracellular fraction (I) were

839 subjected to Western blot analysis and $\alpha 3$ -integrins and $\beta 1$ -integrins were probed, as
 840 well as actin to control for purity of the surface fractions. Quantification for $\alpha 3$ - (D)
 841 and $\beta 1$ - (E) subunit-composed integrins from $n = 3$ independent experiments. (F) – (H)
 842 LecB was applied basolaterally to MDCK cells for the indicated time periods followed
 843 by basolateral application of activation-specific anti- $\beta 1$ -integrin antibodies to live cells.
 844 After fixation, the signal from bound anti- $\beta 1$ -integrin antibodies in randomly chosen
 845 regions of interest was measured and normalized to the cell number in the regions ($n =$
 846 5 for one experiment). The graphs show the mean value from $n = 3$ experiments with
 847 the activating anti- $\beta 1$ -integrin antibody 9EG7 (F), and the inhibitory anti- $\beta 1$ -integrin
 848 antibodies mAB 13 (G) and AIIB2 (H).

Figure 4: Mechanism of LecB-mediated integrin internalization via crosslinking glycosphingolipids and integrins

(A) LecB-Cy3 (15 μ g/ml, red) was applied to GUVs containing fucosylated glycosphingolipids bearing the Lewis a antigen (Lewis a) or the non-fucosylated precursor lactotetraosylceramide (Lc4cer) and BODIPY-FL-C5-HPC (bodipy; green) as a membrane marker. Confocal sections along equatorial planes of the GUVs are displayed; white arrows point to membrane invaginations caused by LecB. (B) Subconfluent MDCK cells grown on glass cover slips were energy-depleted (e.d.) or left untreated (no e.d.). LecB-Cy3 (red) was applied to the cells for 1 h, cells were fixed, and stained for β 1-integrin (green). Confocal x-y sections at the level of the cell adhesion to the glass cover slip are displayed.

Figure 5: LecB inhibits epithelial wound healing

863 (A) – (C) Polarized monolayers of MDCK cells grown in 12 well plates were wounded
 864 with a pipet tip and imaged with a wide field microscope at the indicated time points to
 865 observe wound closure. In (A) cells were treated with LecB and/or L-fucose (43 mM)
 866 to block LecB, whereas in (B) increasing concentrations of LecB were used. The
 867 quantification of the migration speeds of the wound edges from the latter experiment
 868 (C) shows that concentrations larger than 50 $\mu\text{g/ml}$ LecB completely inhibit wound
 869 healing; $n = 3$. (D) Polarized monolayers of MDCK cells stably expressing the plasma
 870 membrane marker ML-GFP (green) grown on chambered cover glasses were wounded
 871 and left untreated (ctrl) or treated with LecB followed by live imaging of the wound
 872 edge by confocal microscopy. Lamellipodia are indicated with white arrows. (E)
 873 Polarized MDCK monolayers grown on chambered cover glasses were wounded and
 874 treated with LecB-Alexa488 (green) for 3 h. Cells were fixed and stained for $\beta 1$ -integrin
 875 (red). A x-y confocal section at half height of the cells is shown. White arrows point to
 876 internalized $\beta 1$ -integrins co-localizing with LecB-Alexa488; the dashed line outlines
 877 the wound edge.

Figure 6: LecB promotes crawling of *P. aeruginosa* underneath cells

(A) Sparsely seeded MDCK cells were incubated with GFP-tagged PAO1-wt or LecB-deficient PAO1-dLecB (green) at an MOI of 50 for 1 h. After fixation, β 1-integrins were stained in red. For each condition, a confocal x-y section at the level of cell adhesion to the substrate, which was taken from a complete three-dimensional confocal stack is displayed. White arrows indicate bacteria underneath cells. (B) – (D) After carrying out an experiment as described in (A) but with indicated MOIs and incubation periods, the numbers of bacteria underneath cells were determined per cell. Each data point represents an individual cell and the black marks indicate the mean and the SEM.

888 For evaluating statistical significance, Mann-Whitney testing using GraphPad Prism 5
889 was applied, **** denotes $p < 0.0001$.